Clinical Trial OutcomesSkepticism grows around the potential of IO combinations without chemotherapy or targeted agents in anti-PD-(L)1 refractory settings, potentially impacting future stock performance.
Financial PerformanceDespite beating consensus estimates on net loss per share, the company's financial losses may continue to weigh on investor sentiment.
Market ReactionThe stock's significant drop reflects investor concerns over the lack of improved average durability of benefit, casting doubts on the company's competitive edge.